Aura Biosciences, Inc.

NASDAQ:AURA

Biotechnology

Healthcare
$7.14 -1.43%

-$0.09 today

Market cap
$743.09M
Beta
0.39
P/E (TTM)
-3.7
EPS (TTM)
-$1.67
52W Low $4.73High $9.54

Volume 0.69M

Average 0.52M

AURA Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Aura Biosciences, Inc.NASDAQ: AURA

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 67.45M shares rose 34.6% year over year, ahead of the +26.5% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 11.8% from the prior quarter. Over 3 fiscal years it compounded at +26.3% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +34.6% holds above the trailing-twelve-month pace of +26.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
67.45M+11.8% QoQ
Last fiscal yearDec 2025
60.34M+21.5% YoY
LTMMar 2026
62.93M+26.5% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+34.6%——
1 year+21.5%——
3-year CAGR+26.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
60.34M USD
Year-over-year change
+21.5%
4-year CAGR
+19.9%

Weighted Avg Shares (Diluted) vs competitors

How AURA compares with its peers on the latest reported figures

  • AURA's LTM Mar 2026 weighted avg shares (diluted) of 62.93M shares is the 7th highest of the 11 companies compared; the peer median is 66.22M shares.
  • Its year-over-year change of +26.5% is the 7th highest of 11, against a peer median of +27.6%.
  • Over three fiscal years its annual growth of +26.3% compares with a peer median of +28.9%.
AURA Competitors Peer median
Weighted Avg Shares (Diluted) for AURA and competitors
Company Period LTM YoY 3-year CAGR
OCGNOcugen, Inc.LTM Mar 2026307.2M +9.9%+11.8%
IMNMImmunome, Inc.LTM Sep 2026106.83M +34.8%+93.1%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 202677.28M +27.7%+25.2%
BCYCBicycle Therapeutics plcLTM Mar 202669.4M +7.1%+32.7%
WHWKWhitehawk Therapeutics IncLTM Mar 202669.18M +155.7%+40.1%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
AURAAura Biosciences, Inc.LTM Mar 202662.93M +26.5%+26.3%
OCSOculis Holding AGLTM Mar 202654.96M +27.5%+16.9%
AKTSAktis Oncology, Inc.FY202552.52M +50.6%+14.6%
OTLKOutlook Therapeutics, Inc.LTM Mar 202628.35M +14.4%+33.9%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 202612.8M +30.5%+47.3%
Peer median (excluding AURA) 66.22M+27.6%+28.9%

Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue001.3M00
Gross Profit00(1.3M)00
Gross Margin—————
Research & Development25.16M42.24M63.94M73.3M90.3M
Selling, General & Admin10.09M18.06M19.76M22.81M22.49M
Operating Expenses35.25M60.3M83.7M96.12M112.79M
Depreciation & Amortization831K1.18M1.3M1.22M1.13M
EBITDA(34.41M)(57.59M)(74.98M)(85.58M)(104.95M)
EBITDA Margin—————
Operating Income(35.25M)(60.3M)(84.99M)(96.12M)(112.79M)
Operating Margin—————
Interest Income13K1.86M8.59M9.43M6.63M
Interest Expense13K0000
Other Income / Expenses(1K)1.53M8.72M9.31M6.71M
Income Before Tax(35.25M)(58.76M)(76.27M)(86.81M)(106.08M)
Pre-Tax Margin—————
Income Tax Expense00137K112K108K
Net Income(35.25M)(58.76M)(76.41M)(86.92M)(106.19M)
Net Margin—————
EPS (Basic)(1.58)(1.96)(1.93)(1.75)(1.76)
EPS (Diluted)(1.58)(1.96)(1.93)(1.75)(1.76)
Weighted Avg Shares29.21M29.94M39.62M49.65M60.34M
Weighted Avg Shares (Diluted)29.21M29.94M39.62M49.65M60.34M

Aura Biosciences, Inc.

NASDAQ:AURA

Intrinsic Alpha fair value

Locked

Current Price

$7.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.